Juno Therapeutics

Juno Therapeutics develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. The Company is exploring the potential of its CAR and TCR technologies against targets that have the potential to treat cancers beyond B cell malignancies and multiple myeloma, in particular, difficult-to-treat solid organ tumors, such as certain breast, lung and pancreatic cancers.

Employee Rating

4More
TypeSubsidiary
Parent CompanyCelgene
HQSeattle, US
Founded2013
Websitejunotherapeutics.com
Cybersecurity ratingCMore
Juno Therapeutics was founded in 2013 and is headquartered in Seattle, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Juno Therapeutics

Hans Bishop

Hans Bishop

CEO
Hyam Levitsky

Hyam Levitsky

EVP, Chief Scientific Officer
Steve Harr

Steve Harr

CFO & Head of Corporate Development
Bob Azelby

Bob Azelby

EVP, Chief Commercial Officer
Cindy Elkins

Cindy Elkins

Chief Information Officer
Mark Gilbert

Mark Gilbert

SVP, Chief Medical Officer
Show more

Juno Therapeutics Office Locations

Juno Therapeutics has offices in Seattle, Bothell, Brisbane, Göttingen and in 1 other location
Seattle, US (HQ)
400 Dexter Ave N #1200
Bothell, US
1522 217th Pl SE
Brisbane, US
2000 Sierra Point Pkwy
Göttingen, DE
28 Rudolf-Wissell-Straße
München, DE
10 Grillparzerstraße
München, DE
Max-Lebsche-Platz 30
Show all (6)

Juno Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2013

Total Funding

$310 m

Investors

In total, Juno Therapeutics had raised $310 m. Juno Therapeutics is a subsidiary of Celgene

Juno Therapeutics Revenue

Juno Therapeutics's revenue was reported to be $111.87 m in FY, 2017
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

18.2m79.4m111.9m

Revenue growth, %

336%

General and administrative expense

51.1m70.7m108.1m

R&D expense

205.2m264.3m451.5m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

12.5m1.6m9.8m27.6m20.8m19.3m21.3m44.8m

General and administrative expense

6.7m14.9m13.6m16.0m16.8m18.4m20.7m23.6m26.3m

R&D expense

57.8m60.2m11.5m73.7m72.3m60.9m82.9m101.1m140.3m

Operating expense total

64.5m80.4m25.1m89.7m89.1m79.3m103.7m124.7m166.6m
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

252.4m187.9m232.8m

Accounts Receivable

315.0k13.3m13.9m

Prepaid Expenses

13.3m

Inventories

8.4m26.5m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

164.2m39.5m569.1m316.0m285.3m223.4m205.7m218.7m449.8m

Accounts Receivable

9.3m10.6m8.8m10.4m34.3m

Prepaid Expenses

5.1m4.2m5.2m9.0m8.4m13.5m48.5m28.7m10.6m

Current Assets

400.7m307.8m1.2b956.0m974.6m844.8m779.5m736.6m972.5m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(51.8m)(245.6m)(437.1m)

Depreciation and Amortization

2.0k14.2m23.6m

Accounts Payable

(2.7m)3.7m46.9m

Cash From Operating Activities

(103.6m)(189.8m)(225.0m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(65.0m)(130.9m)(154.2m)(71.1m)(135.9m)(192.8m)(82.2m)(182.9m)(301.1m)

Depreciation and Amortization

1.0m2.2m3.6m3.2m6.8m10.4m3.3m9.0m15.7m

Accounts Payable

(27.0k)6.7m16.7m(4.5m)7.9m8.6m28.0m40.0m45.2m

Cash From Operating Activities

(21.6m)(70.2m)49.9m(58.2m)(53.4m)(120.4m)(53.9m)(91.9m)(132.2m)
USDQ1, 2015

Financial Leverage

1.4 x
Show all financial metrics

Juno Therapeutics Operating Metrics

FY, 2016

Patent Applications

481

Patents (Foreign)

86

Patents (US)

72
Show all operating metrics

Juno Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

75/100

SecurityScorecard logo

Juno Therapeutics Online and Social Media Presence

Embed Graph

Juno Therapeutics News and Updates

Pomerantz LLP Announces a Proposed Settlement of a Class Action Lawsuit Involving Purchasers of Juno Therapeutics, Inc. Securities

NEW YORK, Aug. 30, 2018 /PRNewswire/ -- UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF WASHINGTON AT SEATTLE In re JUNO THERAPEUTICS, INC. No. C16-1069-RSM SUMMARY NOTICE OF PROPOSED SETTLEMENT OF CLASS ACTION TO: ALL PERSONS OR ENTITIES THAT PURCHASED OR OTHERWISE ACQUIRED...

Juno Therapeutics CEO Bishop set for $200M+ payday with Celgene buyout

Juno Therapeutics CEO Hans Bishop is in line for a nice payday when his company seals the deal with Celgene. Think $200 million or more.

Juno Therapeutics Frequently Asked Questions

  • When was Juno Therapeutics founded?

    Juno Therapeutics was founded in 2013.

  • Who are Juno Therapeutics key executives?

    Juno Therapeutics's key executives are Hans Bishop, Hyam Levitsky and Steve Harr.

  • How many employees does Juno Therapeutics have?

    Juno Therapeutics has 727 employees.

  • What is Juno Therapeutics revenue?

    Latest Juno Therapeutics annual revenue is $111.9 m.

  • What is Juno Therapeutics revenue per employee?

    Latest Juno Therapeutics revenue per employee is $153.9 k.

  • Who are Juno Therapeutics competitors?

    Competitors of Juno Therapeutics include Kite Pharma, Adaptive Biotechnologies and Biothera.

  • Where is Juno Therapeutics headquarters?

    Juno Therapeutics headquarters is located at 400 Dexter Ave N #1200, Seattle.

  • Where are Juno Therapeutics offices?

    Juno Therapeutics has offices in Seattle, Bothell, Brisbane, Göttingen and in 1 other location.

  • How many offices does Juno Therapeutics have?

    Juno Therapeutics has 6 offices.